Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Consun Pharmaceutical Group Ltd. ( (HK:1681) ) just unveiled an announcement.
Consun Pharmaceutical Group Ltd. reported a significant financial growth for the first half of 2025, with revenue increasing by 23.7% to RMB1,568,588,000 and profit attributable to equity shareholders rising by 24.6% to RMB498,299,000 compared to the same period in 2024. This strong performance is reflected in the declared interim dividend of HKD0.33 per share, indicating a positive outlook for stakeholders and reinforcing the company’s robust market positioning.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development, manufacturing, and sale of pharmaceutical products.
Average Trading Volume: 2,561,143
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.09B
For an in-depth examination of 1681 stock, go to TipRanks’ Overview page.